A drug from The Scripps Research Institute that revolutionized treatment of a deadly blood cancer called hairy cell leukemia is also useful in another kind of the disease, according to a study ...

Patients with multiple sclerosis (MS) treated with cladribine tablets (Mavenclad) were less likely to experience disease relapse than those who were treated with other oral disease-modifying therapies ...

Phase II Trial of Autologous Tumor Vaccination, Anti-CD3-Activated Vaccine-Primed Lymphocytes, and Interleukin-2 in Stage IV Renal Cell Cancer Purpose: Hairy cell leukemia (HCL) is an uncommon, ...

Cladribine tablets are approved for several indications, namely highly active forms of relapsing-remitting MS and certain forms of leukemia. MS represents the largest market segment for the sale of ...

"Accelerated development of a proprietary Cladribine ODF formulation for the treatment of MS has become a top priority for BioNxt," said Hugh Rogers, CEO & Director of BioNxt. "In just a few years the ...

LONDON — Merck Serono has decided to try for a second time to gain approval for an oral formulation of cladribine as a treatment for multiple sclerosis (MS), with longer-term follow-up of clinical ...

June 9, 2009 (Atlanta, Georgia) — Oral short-course treatment with cladribine, at 2 dosing levels, demonstrated efficacy compared with placebo in patients with relapsing-remitting multiple sclerosis ...

In June 2017, the European Medicines Agency (EMA) approved oral cladribine for the treatment of relapsing–remitting multiple sclerosis (RRMS). However, cladribine is not a new drug, and its efficacy ...

The EMA has approved cladribine tablets for the treatment of multiple sclerosis. The drug is not new, and the journey to its approval has been a long one, but the old concepts that cladribine therapy ...

The appraisal committee considered evidence submitted by Merck Serono and a review of this submission by the evidence review group (ERG). See the committee papers for full details of the evidence.

The appraisal committee considered evidence submitted by Merck Serono and a review of this submission by the evidence review group (ERG). See the committee papers for full details of the evidence.